PharmAust has signed an agreement with US company Catalent Pharma Solutions for the GMP-grade manufacture of its “Monepantel” anti-cancer drug for its upcoming clinical trials in dogs. Manufacturing the drugs to GMP standards will enable the resultant data to be admissible to the US FDA in support of new drug registration programs, a key milestone for PharmAust.
Related Data & Insights
-
-
Rank Company Revenue 128th PharmAust $3.8m 137th Adisyn $2.9m 138th rent.com.au $2.8m 141st Douugh $2.5m 142nd Hazer Group $2.4m 201 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Data & Insights
Mentioned Organisations
Related Articles
05 Feb 2024
Board Moves February 5, 2024
28 Aug 2023
Board Moves August 28, 2023
23 Jul 2021
PharmAust looks to patent anti-cancer drug
Subscribe today for award-winning, unbiased and trusted journalism
Subscription OptionsX